These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 7768525)

  • 1. Hepatic lidocaine metabolism and liver histology.
    Fabbri A; Bianchi GP; Marchesini G
    Hepatology; 1995 Jun; 21(6):1761-2. PubMed ID: 7768525
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis.
    Shiffman ML; Luketic VA; Sanyal AJ; Duckworth PF; Purdum PP; Contos MJ; Mills AS; Edinboro LE; Poklis A
    Hepatology; 1994 Apr; 19(4):933-40. PubMed ID: 8138268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of hepatic lidocaine metabolism to monitor patients with chronic liver disease.
    Shiffman ML; Luketic VA; Sanyal AJ; Thompson EB
    Ther Drug Monit; 1996 Aug; 18(4):372-7. PubMed ID: 8857553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Monoethylglycinexylidide (MEGX)-test. A test for the assessment of prognosis before and after liver transplantation].
    Reichel C; Wienkoop G; Nacke A; Spengler U
    Dtsch Med Wochenschr; 1995 Feb; 120(6):179-83. PubMed ID: 7851289
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatic lidocaine metabolism is useful in the selection of patients in need of liver transplantation.
    Luketic VA; Shiffman ML; Fisher RA; Sanyal AJ; Purdum PP; Posner MP
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1072-4. PubMed ID: 8442046
    [No Abstract]   [Full Text] [Related]  

  • 6. Lidocaine metabolism as an index of liver function in hepatic transplant donors and recipients.
    Schroeder TJ; Gremse DA; Mansour ME; Theuerling AW; Brunson ME; Ryckman FC; Suchy FJ; Penn I; Alexander JW; Pesce AJ
    Transplant Proc; 1989 Feb; 21(1 Pt 2):2299-301. PubMed ID: 2652744
    [No Abstract]   [Full Text] [Related]  

  • 7. The low-dose monoethylglycinexylidide test: assessment of liver function with fewer side effects.
    Reichel C; Nacke A; Sudhop T; Wienkoop G; Lüers C; Hahn C; Pohl C; Spengler U; Sauerbruch T
    Hepatology; 1997 Jun; 25(6):1323-7. PubMed ID: 9185746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological comparison of donor livers and lidocaine metabolism in the utilization of organs for liver transplantation.
    Rosenlof LK; Sawyer RG; Broccoli AV; Ishitani MB; Stevenson WC; Pruett TL
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1662-3. PubMed ID: 8442229
    [No Abstract]   [Full Text] [Related]  

  • 9. Lignocaine metabolism and MEGX production in the liver transplant donor.
    Potter JM; Hickman PE; Balderson G; Lynch SV; Strong R
    Transplant Proc; 1992 Feb; 24(1):198-9. PubMed ID: 1539243
    [No Abstract]   [Full Text] [Related]  

  • 10. Monoethylglycinexylidide production and prediction of hepatic histology.
    Fabbri A; Bianchi GP; Marchesini G
    Ital J Gastroenterol; 1995; 27(1):40-1. PubMed ID: 7795287
    [No Abstract]   [Full Text] [Related]  

  • 11. Hepatic lidocaine metabolism in chronic hepatitis C virus hepatitis with or without steatosis.
    Taliani G; Duca F; Lecce R; Livoli D; Pasquazzi C; De Bac C
    Hepatology; 1995 Jun; 21(6):1760-1. PubMed ID: 7605510
    [No Abstract]   [Full Text] [Related]  

  • 12. [Role of lidocaine metabolism studies in the diagnosis of liver diseases].
    Ol'rikh M; Kukes VG; Igonin AA
    Klin Lab Diagn; 2000 Jul; (7):8-11. PubMed ID: 10981386
    [No Abstract]   [Full Text] [Related]  

  • 13. [Dynamic liver function study using the lidocaine test].
    Sídlová K; Průsa R
    Cas Lek Cesk; 2000 Sep; 139(19):604-5. PubMed ID: 11192753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoethylglycinexylidide formation in compensated cirrhosis: correlation with Child-Pugh score.
    Testa R; Borzone S; Campo N; Alvarez S; Caglieris S; Arzani L; Risso D; Lantieri PB; Celle G
    Transplant Proc; 1994 Dec; 26(6):3624-5. PubMed ID: 7998297
    [No Abstract]   [Full Text] [Related]  

  • 15. Hepatic lidocaine metabolism and complications of cirrhosis. Implications for assessing patient priority for hepatic transplantation.
    Shiffman ML; Fisher RA; Sanyal AJ; Edinboro LE; Luketic VA; Purdum PP; Raymond P; Posner MP
    Transplantation; 1993 Apr; 55(4):830-5. PubMed ID: 8475560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetics of lidocaine after intravenous and oral administration in patients with liver cirrhosis].
    Fuchshofen M; Zilly W; Epping J; Richter E
    Verh Dtsch Ges Inn Med; 1978; (84):1110-2. PubMed ID: 741898
    [No Abstract]   [Full Text] [Related]  

  • 17. MEGX as a test of donor liver function.
    Balderson GA; Potter JM; Hickman PE; Chen Y; Lynch SV; Strong RW
    Transplant Proc; 1992 Oct; 24(5):1960-1. PubMed ID: 1412928
    [No Abstract]   [Full Text] [Related]  

  • 18. Quantitative liver testing with MEG-X: more optimism?
    Ziebell J; Shaw-Stiffel TA
    Hepatology; 1995 Jun; 21(6):1762-4. PubMed ID: 7768526
    [No Abstract]   [Full Text] [Related]  

  • 19. 13CO2 excretion in breath of normal subjects and cirrhotic patients after 13C-aminopyrine oral load. Comparison with MEGX test in functional differentiation between chronic hepatitis and liver cirrhosis.
    Fasoli A; Giannini E; Botta F; Romagnoli P; Risso D; Celle G; Testa R
    Hepatogastroenterology; 2000; 47(31):234-8. PubMed ID: 10690614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitation of intrinsic drug-metabolizing capacity in human liver biopsy specimens: support for the intact-hepatocyte theory.
    Meyer B; Luo HS; Bargetzi M; Renner EL; Stalder GA
    Hepatology; 1991 Mar; 13(3):475-81. PubMed ID: 1671846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.